Founder of Burning Rock, established Burning Rock in 2014, engaged in investment of medical fields; with successful experience in establishing and operating a start-up team; with six years of working experience in the field of life science.
Established Burning Rock
Investment manager of top-rank VC Northern Light Venture Capital
MBA from Columbia University
General manager of BioTek Instrument China Region
Cell biology master of Peking Union Medical College
Co-founder of Burning Rock. With 13 years of experience in the field of bioinformatics and translational medicine, mastered internationally leading technologies, accumulated R& D experience in tumor individualistic diagnosis and treatment related areas such as NGS data analysis, molecular diagnosis,etc.
Novartis (China) R& D Center: Supervisor of the bioinformatics platform
Chief Statistical Analyst of Novartis (America), University of Pennsylvania
Experiment designer and data analyst of Sloan-Katherine Cancer Center of New York
University of Pennsylvania: Biostatistics Ph. D.
University of Texas: Statistics and Applied Mathematics Master
With 14 years of clinical R&D experience with a foreign-owned pharmaceutical company. Ever took charge of clinical development of several important declining drugs in China, such as Crizotinib, ceritinib, axitinib, velcade, etc.
Novartis: Took charge of all research strategies and projects of solid tumors in China. A senior person with richest development experience of ALK TKI in China (no one else has the all-course experience in the development of ALK TKI of the first and second generation)
Pfizer: Took charge of all clinical researches of star drug Crizotinib. A soul-level tutor and person in charge of development of Crizotinib in China.
Worked in a tumor hospital of Chinese Academy of Medical Sciences for five years
With working experience in the field of NGS for over 10 years. Ever participated in research and development of several products, successfully released kits such as Infinium Omni 2.5M-8, 5M-4 gene sub-typing chip, TruSeq Dual Index Sequencing, TruSeq DNA Ht, TruSeq Stranded RNA HT, TruSeq Exome, TruSeq Synthetic Long-Read DNA as a leader of the core team, and made outstanding contribution to the fast development of NGS
A senior scientist of Illumina. A senior researcher of genome science department of Howard Hughes Institute of Medicine of University of Washington
Duke University: Ph.D. of molecular genetics and microbiology
Focused on sales of in vitro diagnostic agent for above 16 years, with rich marketing management and business expansion capabilities.
Worked as a sales supervisor for South China region in QIAGEN Business Management (Shanghai) Co., Ltd.
Worked as a market explorer in South China regionBeijing Jinpujia Medical Technology Co., Ltd.
Gene (Hong Kong) Co., Ltd.: Sales of Denmark DAKO, America BD, Abbott VYSIS diagnosis reagent, pathology, streaming and blood departments of Guangdong and Fujian
Shandong Liming Polytechnic Vocational College
With above ten years of experience in life science and medicine and with rich experience in marketing and project management
Co-founder of Burning Rock
Gene Co., Ltd. General manager for China Region with the department of large applied instrument
Gene Co., Ltd. Project manager for China Region (applied industry)
Nanjing Normal University Biotech
Peng Wenfeng, Marketing Director
With 14 years of product and market management experience in the field of anti-tumor with a foreign-owned pharmaceutical enterprise.
Pfizers tumor market manager: Responsible for market management in the field of gastrointestinal tumor and blood tumor;
Tumor business department of Novartis: The first batch of salespersons for Glivec, the first molecular target anti-tumor drug, and later took charge of product management for first-line indications of blood tumor of Glivec and before the marketing of the second generation product Tasigna at the Central Market Department;
MBA of Fudan University, bachelor of Hunan Medical University.